Key result
Female sex is linked to ~80% higher nonadherence to post-stroke lipid-lowering therapy versus men.
Why the study?
Does female sex increase the risk of nonadherence to secondary stroke prevention medications in patients with first-ever ischemic stroke?
Observational (n=1,324)
Does female sex increase the risk of nonadherence to secondary stroke prevention medications in patients with first-ever ischemic stroke?
Relative Risk: 1.8 (95% CI 1.14–2.84)
Women with first-ever ischemic stroke have higher rates of nonadherence to cholesterol-lowering and antiplatelet medications compared to men at 90 days post-stroke.
Social factors may explain higher nonadherence in women; leaves open whether targeted interventions improve outcomes.
Background More women than men experience recurrent strokes. Medication adherence is critical to prevent recurrence; however, studies investigating sex differences are limited. We examined sex differences in poststroke medication adherence, overall and by drug class, and identified influencing factors. Methods and Results Patients with first‐ever ischemic stroke were identified from a population‐based study (2008–2019). At 90 days after a stroke, self‐reported medication adherence was defined as never or rarely missing a dose in a typical week for each secondary stroke prevention medication (antihypertensives, cholesterol‐lowering drugs, antiplatelets, anticoagulants). We generated prevalence ratios (PRs) using modified Poisson models to assess sex differences with and without adjustment for potential confounding factors, including demographics, social factors, health system–related, lifestyle‐related, health condition–related, prestrokehealth–related, and stroke‐related factors. Among 1324 participants (48.4% women, 58.0% Mexican American individuals), women were more likely to report nonadherence to cholesterol‐lowering drugs (PR, 1.80 [95% CI, 1.14–2.84]) and antiplatelets (PR, 1.53 [95% CI, 1.003–2.34]). Adjusting for obesity attenuated while adjusting for age, marital status, access to care, smoking, and alcohol consumption accentuated sex differences. Race and ethnicity modified the sex difference in nonadherence to cholesterol‐lowering drugs ( P interaction =0.054) such that the sex difference was larger in Mexican American individuals (PR, 3.00 [95% CI, 1.65–5.48]) than in non‐Hispanic White individuals (PR, 1.30 [95% CI, 0.52–3.27). No significant sex differences were found for nonadherence to antihypertensives and overall nonadherence. Conclusions Poststroke medication nonadherence was more prevalent among women than men. This was partially due to the confounding effects of lifestyle, marital status, and access to care, suggesting potential subgroups for interventions to improve adherence.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted an observational in first-ever ischemic stroke (n=1,324). Female sex vs. Male sex was evaluated on Nonadherence to cholesterol-lowering drugs (PR 1.80, 95% CI 1.14-2.84). Women were more likely than men to report nonadherence to cholesterol-lowering drugs (PR 1.80; 95% CI 1.14-2.84) and antiplatelets (PR 1.53; 95% CI 1.003-2.34) at 90 days post-stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: